Results First Posted : July 10, Last Update Posted : July 10, Study Description. We propose to treat between 10 and 20 patients with chronic delta hepatitis with pegylated alpha interferon for up to five years. Patients will be monitored for at least three months with regular testing for ALT levels and will undergo admission for a thorough medical evaluation, portal pressure measurement and percutaneous liver biopsy before treatment.
Pegylated interferon will then be started in a dose of mcg weekly. At each clinic visit, patients will be questioned about side effects and symptoms and have blood taken for complete blood counts and routine liver tests ALT, AST, alkaline phosphatase, direct and total bilirubin, and albumin. The dose of pegylated interferon will be adjusted based upon side effects and changes in ALT levels, aiming for optimal suppression of ALT elevations with acceptable tolerance.
Log in to Wiley Online Library
At 48 weeks one year and every 96 weeks two years thereafter, patients will be readmitted to the NIH Clinical Center for repeat thorough medical evaluation, portal pressure measurement and liver biopsy. The primary endpoint of therapy will be improvements in hepatic histology on liver biopsy done after 3 years of pegylated alpha interferon therapy. Patients will be maintained on pegylated interferon if it is adequately tolerated and there is an adequate "histological response," as defined by at least 3 point improvement in inflammatory score or 1 point improvement in fibrosis score of the HAI at each liver biopsy.
Therapy will be stopped for: 1 intolerance to alpha interferon which will be carefully defined , 2 lack of improvement in hepatic histology after 1, 3, or 5 years of therapy histological nonresponse , or 3 a "complete response," i. FDA Resources. Arms and Interventions. Outcome Measures. Eligibility Criteria.
Recombinant Human Interferon alpha 2b Protein
Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Presence of anti-HDV in serum. Presence of HDV antigen in liver tissue. Written informed consent. Active HBV replication will not exclude patients. All ethnicities. Immunosuppressive therapy within the last 6 months. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.
Human Interferon Gamma ELISPOT Kit (ab) | Abcam
More Information. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci.
amalsadoo.tk Hepatitis delta virus as a global health problem. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen.
An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. Epub Jan National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Hepatitis D. Drug: Peginterferon Alpha-2a. Phase 2. Study Type :. Actual Enrollment :. As such, viruses have evolved diverse mechanisms to subvert the antiviral effects of interferons. Herpes simplex virus type 1 HSV-1 is a. Herpes simplex virus type 1 HSV-1 is a large deoxyribonucleic acid virus best known for its ability to cause cold sores in infected individuals.
Plaque reduction assays were used to determine that the immediate early HSV-1 gene product ICP0 functions in part to ensure successful replication in the presence of an IFN-induced antiviral response. Finally, nuclear run-on assays demonstrated that ICP0 functions to overcome IFN-induced blocks to virus transcription. The methods used in these studies are described in detail in this section. Antibody Data Search Beta. Authors: Karen Mossman 1. Karen Mossman 1. Full text PDF Related articles.
- Interferon gamma Antibody AP | Proteintech.
- Dante and Italy in British Romanticism (Nineteenth-Century Major Lives and Letters).
- Contrastive reasons.
Abstract A defining hallmark of the type 1 interferons IFNs is their ability to interfere with virus replication. Related articles Based on techniques. Tremblay et al.
References Isaacs, A. The interferon. London Serv.